United Therapeutics Unveils Positive Data Across Pulmonary Hypertension and Fibrosis Trials at ATS 2026 — United Therapeutics Corporation

Event summary

United Therapeutics will present 12 new data sets at ATS 2026, including pivotal TETON-1 and ADVANCE OUTCOMES studies.
Key findings include early treatment benefits in pulmonary arterial hypertension (PAH) and real-world dosing insights for treprostinil.
Presentations cover both commercial and developmental programs, including PHINDER, ARTISAN, and TETON-PPF studies.
Conference runs May 15-20 in Orlando, with sponsored symposia on unmet needs in IPF and PAH treatment strategies.

The big picture

United Therapeutics' data presentations at ATS 2026 underscore its focus on addressing critical unmet needs in pulmonary hypertension and fibrosis. The company's pipeline diversification—spanning inhaled, oral, and parenteral therapies—positions it to compete in a landscape increasingly dominated by combination therapies and disease-modifying approaches. With IPF and PAH markets projected to grow significantly, the strategic emphasis on clinical insights could accelerate adoption of its differentiated treatment paradigms.

What we're watching

Clinical Validation: Whether TETON-1 and ADVANCE OUTCOMES data can position United Therapeutics as a leader in PAH and IPF treatments.
Regulatory Pathways: The pace at which positive trial results translate into expanded indications or approvals for treprostinil formulations.
Market Differentiation: How real-world evidence from PHINDER and ARTISAN studies will impact competitive positioning against emerging therapies like sotatercept.